Melanoma immunotherapy: strategies to overcome pharmacological resistance

References

• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Melero I, Crocenzi TS, Welling TH, et al. Phase I/II safety and anti-tumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015;33(Suppl18):LBA101.
   Google Scholar
• Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–1598.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Mcdermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II Trial. J Clin Oncol. 2015;33(13):1430–1437.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Hamid C, Robert A, Daud F, et al. Five year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vetizou M, Daillere R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsicand- extrinsicfactors. Immunity. 2016;44(6):1255–1269.
   PubMed Web of Science ®Google Scholar
• Bai J, Gao Z, Li X, et al. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1blockade. Oncotarget. 2017;8(66):110693–110707.
   PubMedGoogle Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights intoT cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499.
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the anti-tumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393–403.
   PubMed Web of Science ®Google Scholar
• Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–216.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumor immunity. Nature. 2015;523(7559):231–235.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6(7):722–729.
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412–416.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Seto T, Sam D, Pan M. Mechanisms of primary and secondary resistance to immune checkpoint inhibitors. Med Sci (Basel). 2019;7:pii: E14.
   Google Scholar
• Linehan DC, Goedegebuure PS. CD25+CD4+ regulatory T-cells in cancer. Immunologic Res. 2005;32(1–3):155–168.
   PubMed Web of Science ®Google Scholar
• Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006;13(9):1252–1258.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201.
   PubMed Web of Science ®Google Scholar
• Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915–919.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–1609.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, et al. Cancer immunology the “cancer immunogram. Science. 2016;352(6286):658–660.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–465.
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423–1427.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428–1433.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prietoartin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224(1):166–182.
   PubMedGoogle Scholar
• Laffery KJ, Prowse SJ, Simeonovic CJ, et al. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol. 1983;1(1):143–173.
   PubMedGoogle Scholar
• Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7(1):445–480.
   PubMedGoogle Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Kurtulus S, Smyth MJ, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112–120.
   PubMed Web of Science ®Google Scholar
• Ward-Kavanagh LK, Lin WW, Šedý JR, et al. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity. 2016;44(5):1005–1019.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–584.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151–160.
   PubMed Web of Science ®Google Scholar
• Hersh EM1, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011;29(3):489–498.
   PubMed Web of Science ®Google Scholar
• Maio M, Di Giacomo AM, Robert C, et al. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 2013;25(2):166‐172.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Langer CJ, Gadgeel S, et al. 24-month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2019;14(1):124–129.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower150 study group atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Capuzzo F, McCLeod M, Hussein M, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018;29(Suppl8). DOI:10.1093/annonc/mdx807.
   Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.
   PubMedGoogle Scholar
• Martin K, Schreiner J, Zippelius A. Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Front Immunol. 2015;6:501.
   PubMed Web of Science ®Google Scholar
• Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40(1):25–37.
   PubMed Web of Science ®Google Scholar
• Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–1332.
   PubMed Web of Science ®Google Scholar
• Sharma A1, Bode B, Wenger RH, et al. γ-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One. 2011;6(11):e28217.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent anti-tumor immunity in immunogenic tumors. Immunity. 2014;41(5):843‐852.
   Web of Science ®Google Scholar
• Demaria S, awashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2):728–734.
   PubMed Web of Science ®Google Scholar
• Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–349.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Reddy S, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012;5(6):404–407.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–5388.
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Mok S, Comin-Anduix B, et al. Combined treatment with dabrafenib and trametinib with immunestimulating antibodies for BRAF mutant melanoma. OncoImmunology. 2015;5(7):e1052212.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213–5219.
   PubMed Web of Science ®Google Scholar
• Bradley SD, Chen Z, Melendez B, et al. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol Res. 2015;3(6):02–609.
   Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Chodon T, Sazegar H, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010;16(24):6040–6048.
   PubMed Web of Science ®Google Scholar
• Knight DA, Ngiow SF, Li M, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013;123(3):1371–1381.
   PubMed Web of Science ®Google Scholar
• Minor DR, Puzanov I, Callahan MK, et al. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015;28(5):611–612.
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Crozet L, Damotte D, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 2014;74(18):5008–5018.
   PubMed Web of Science ®Google Scholar
• Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014;33(27):3485–3495.
   PubMed Web of Science ®Google Scholar
• Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93(6):847–863.
   PubMed Web of Science ®Google Scholar
• Bald T, Landsberg J, Lopez-Ramos D, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4(6):674–687.
   PubMed Web of Science ®Google Scholar
• Millward M, Underhill C, Lobb S, et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumors. Br J Cancer. 2013;108(10):1998–2004.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175(9):6169–6176.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712–720.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Ott PA, Naing A, et al. The personalized vaccine NEO-PV-01, with anti-PD-1, induces neoantigen-specific de novo immune responses in patients with advanced or metastatic melanoma: association with clinical outcomes. Presented at: American Association for Cancer Research (AACR) Annual Meeting 2019; 2019 March 29-April 3; Atlanta, GA.
   Google Scholar
• Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355–366.
   PubMed Web of Science ®Google Scholar
• Li B, VanRoey M, Wang C, et al. Anti–programmed Death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15(5):1623–1634.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–3603.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935–1945.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–883.
   PubMed Web of Science ®Google Scholar
• Bajor DL, Mick R, Riese MJ, Richman LP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan B, Schuchter LM, Amaravadi R, et al. Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma. Cancer Res. 2015;75(21):4494–4503. Abstract CT137.
   PubMedGoogle Scholar
• Zippelius A, Schreiner J, Herzig P, et al. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015;3(3):236–244.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• Huang RR, Jalil J, Economou JS, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011;17(12):4101–4109..
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65(1):185–202.
   PubMedGoogle Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275–4280.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Fujita T, Ukyo N, Hori T, et al. Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett. 2006;106(1):27–33.
   PubMed Web of Science ®Google Scholar
• deBarros A, Chaves-Ferreira M, d’Orey F, et al. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes. Eur J Immunol. 2011;41(1):195–201.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271–285.
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Postel-Vinay S, Rusakiewicz S, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50–66.
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013;73(24):7189–7198.
   PubMed Web of Science ®Google Scholar
• Buchan S, Manzo T, Flutter B, et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol. 2015;194(1):125–133.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:7.
   PubMedGoogle Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable Stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–2626.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Ribas A, et al. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). J Immunother Cancer. 2015;3(2):1.
   PubMedGoogle Scholar
• Long G, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(15_suppl):9568.
   Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166–179.
   PubMed Web of Science ®Google Scholar
• Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21(35):5496–5503.
   PubMed Web of Science ®Google Scholar
• Héninger E, Krueger TE, Lang JM. Augmenting anti-tumor immune responses with epigenetic modifying agents. Front Immunol. 2015;6:29.
   PubMed Web of Science ®Google Scholar
• Vo DD, Prins RM, Begley JL, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009;69(22):8693–8699.
   PubMed Web of Science ®Google Scholar
• Woods DM, Sodre AL, Villagra A, et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015;3(12):1375–1385.
   PubMed Web of Science ®Google Scholar
• Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409–421.
   PubMed Web of Science ®Google Scholar
• Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13(1):23–35.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol.Immunother. 2014;63(3):247–257.
   PubMed Web of Science ®Google Scholar
• De Henau O, Rausch M, Winkler D, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kg in myeloid cells. Nature. 2016;539(7629):443–447.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kg is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67.
   PubMed Web of Science ®Google Scholar
• Chouaib S, Noman MZ, Kosmatopoulos K. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36(4):439–445.
   PubMed Web of Science ®Google Scholar
• Zhang H, Conrad DM, Butler JJ, et al. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic Adenosine 3′,5′-Monophosphate and Phosphatases. J Immunol. 2004;173(2):932–944.
   PubMed Web of Science ®Google Scholar
• Mittal D, Sinha D, Barkauskas D, et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res. 2016;76(15):4372–4382.
   PubMed Web of Science ®Google Scholar
• Young A, Mittal D, Stagg J, et al. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014;4(8):879–888.
   PubMed Web of Science ®Google Scholar
• Ma DF, Kondo T, Nakazawa T, et al. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol. 2010;41(11):1550–1557.
   PubMed Web of Science ®Google Scholar
• Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA. 2013;110(27):11091–11096.
   PubMed Web of Science ®Google Scholar
• Leclerc BG, Charlebois R, Chouinard G, et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res. 2016;22(1):158–166.
   PubMed Web of Science ®Google Scholar
• Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75(21):4494–4503.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Slaney CY, Milenkovski N, et al. CD73: A potential biomarker for anti-PD-1 therapy. Oncoimmunology. 2015;4(11):e1046675.
   PubMed Web of Science ®Google Scholar
• Iannone R, Miele L, Maiolino P, et al. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. 2014;4(2):172–181.
   PubMed Web of Science ®Google Scholar
• Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74(14):3652–3658.
   PubMed Web of Science ®Google Scholar
• Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumor cells. Nat Commun. 2018;9(1):948.
   PubMed Web of Science ®Google Scholar
• Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev. 2011;241(1):260–268.
   PubMedGoogle Scholar
• Oida T, Zhang X, Goto M, et al. CD4 + CD25 − T cells that express latency-associated peptide on the surface suppress CD4 + CD45RB high -Induced colitis by a TGF-β-dependent mechanism. J Immunol. 2003;170(5):2516–2522.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787.
   PubMed Web of Science ®Google Scholar
• Arce Vargas F, Furness AJS, Solomon I, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017;46(4):577–586.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking anti-tumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110(44):17945–17950.
   PubMed Web of Science ®Google Scholar
• Chang D-K, Sui J, Geng S, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012;11(11):2451–2461.
   PubMed Web of Science ®Google Scholar
• Gil M, Komorowski MP, Seshadri M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014;193(10):5327–5337.
   PubMed Web of Science ®Google Scholar
• Lebrun -J-J. The dual role of TGF in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;2012:381428.
   PubMedGoogle Scholar
• Lin RL, Zhao LJ. Mechanistic basis and clinical relevance of the role of transforming growth factor-beta in cancer. Cancer Biol Med. 2015;12(4):385–393.
   PubMed Web of Science ®Google Scholar
• Massague J. TGF beta in Cancer. Cell. 2008;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Hanks BA, et al. Combinatorial TGF-{beta} signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E-PTEN−/−transgenic model of melanoma. Chicago, ASCO Annual Meeting Proceedings. 2014.
   Google Scholar
• Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75(11):2232–2242.
   PubMed Web of Science ®Google Scholar
• Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250‐254.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits anti-tumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):pii: eaak9670.
   PubMed Web of Science ®Google Scholar
• Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD- L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):pii: eaak9679.
   Web of Science ®Google Scholar
• Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632‐642.
   Web of Science ®Google Scholar
• Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014;63(7):721–735.
   PubMed Web of Science ®Google Scholar
• Yoshida R, Imanishi J, Oku T, et al. Induction of pulmonary indoleamine 2, 3-dioxygenase by interferon. Proc Natl Acad Sci U S A. 1981;78(1):129–132.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–1402.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Li Y, et al. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13(2):412–424.
   PubMed Web of Science ®Google Scholar
• Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-Dioxygenase–expressing dendritic cells mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196(4):447–457.
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002;196(4):459–468.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–1077.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003;24(5):242–248.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–1402.
   PubMed Web of Science ®Google Scholar
• Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2(1):3.
   PubMedGoogle Scholar
• Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520–3530.
   PubMed Web of Science ®Google Scholar
• Soliman HH, Minton SE, Han HS, et al. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016;7(16):22928–22938.
   PubMedGoogle Scholar
• Gibney G, Hamid O, Lutzky J, et al. 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur J Cancer. 2015;51:S106–S107.
   Web of Science ®Google Scholar
• Benson DM, Caligiuri MA. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res. 2014;2(2):99–104.
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065–1073.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clin Cancer Res. 2014;20(20):5157–5170.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–472.
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670–1690.
   PubMed Web of Science ®Google Scholar
• Hu W, Li X, Zhang C, et al. Tumor-associated macrophages in cancers. Clin Transl Oncol. 2016;18(3):251–258.
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–859.
   PubMed Web of Science ®Google Scholar
• Tham M, Khoo K, Yeo KP, et al. Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma. Oncotarget. 2015;6(26):22857–22868.
   PubMedGoogle Scholar
• Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the anti-tumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153–161.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD- 1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28(8):1988‐1995.
   PubMed Web of Science ®Google Scholar
• Carleton M, Zhou M, De Henau O, et al. Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy. J Clin Oncol. 2018;36(15_suppl):3025.
   Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD- 1 antibody in cancer. N Engl J Med. 2012;366(26):2443‐2454.
   Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD- L1antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563‐567.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1,PD-1ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064‐5074.
   Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208‐222.
   Web of Science ®Google Scholar
• Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017;23(14):3585‐3591.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016;22(9):2177‐2182.
   Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–2186.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17;7(1):10501.
   PubMed Web of Science ®Google Scholar
• Guo Z, Cheng D, Xia Z, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013;11(1):215.
   PubMedGoogle Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107(17):7875–7880.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol. 2017;35(15_suppl):9520..
   Web of Science ®Google Scholar
• Ascierto PA, Bono P, Bhatia S, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma. Madrid, Spain: ESMO 2017 Congress.
   Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promotingthe generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–937.
   PubMed Web of Science ®Google Scholar
• Lozano E, Dominguez-Villar M, Kuchroo V, et al. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869–3875.
   PubMed Web of Science ®Google Scholar
• Ju SA, Lee SC, Kwon TH, et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumor-infiltrating lymphocytes. Immunol Cell Biol. 2005;83(4):344–351.
   PubMed Web of Science ®Google Scholar
• Chacon JA, Wu RC, Sukhumalchandra P, et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013;8(4):e60031.
   PubMed Web of Science ®Google Scholar
• Li SY, Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol. 2015;5(Suppl 1):47–53.
   Google Scholar
• Chen S, Lee LF, Fisher TS, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149–160.
   PubMed Web of Science ®Google Scholar
• Chester C, Chang S, Kurland JF, et al. Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. J Clin Oncol. 2014;32(15 suppl):3017.
   Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010;5(5):e10436.
   PubMed Web of Science ®Google Scholar
• Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211(4):715–725.
   PubMed Web of Science ®Google Scholar